Hepatitis B Virus: Molecular Virology and Common Mutants

ABSTRACT

A high rate of viral turnover, combined with an error-prone polymerase, results in a very high frequency of mutational events during hepatitis B virus replication. Mutants may accumulate, particularly in individuals at advanced stages of persistent infection and with antibody- and cell-mediated immune responses to the virus. Specific mutants may be selected from these populations, especially by antibody and cytotoxic T lymphocyte responses and by antiviral therapy. In some cases, the mutants may be associated with especially severe acute hepatitis (including acute liver failure) and the development of sequelae such as cirrhosis and hepatocellular carcinoma. Antiviral resistance poses a challenge to therapy that might be overcome by the use of combinations of antiviral drugs.

KEYWORDS

Virus replication - reverse transcriptase - precore mutants - basic core promoter mutations - antibody escape - antiviral resistance

REFERENCES

• 1 Norder H, Courouce A M, Coursaget P et al.. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.  Intervirology. 2004;  47 289-309
• 2 Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes.  Vaccine. 2005;  23 2409-2423
• 3 Nowak M A, Bonhoeffer S, Hill A M, Boehme R, Thomas H C, McDade H. Viral dynamics in hepatitis B virus infection.  Proc Natl Acad Sci USA. 1996;  93 4398-4402
• 4 Harrison T J, Oon C J, Zuckerman A J. A novel antibody escape variant (ala 144) of hepatitis B virus in an identical twin before selection in the mother. In: Nishioka K, Suzuki H, Mishiro S, Oda T Viral Hepatitis and Liver Disease. Tokyo; Springer-Verlag 1994: 248-251
• 5 Sen N, Cao F, Tavis J E. Translation of duck hepatitis B virus reverse transcriptase by ribosomal shunting.  J Virol. 2004;  78 11751-11757
• 6 Hadziyannis S J, Lieberman H M, Karvountzis G G, Shafritz D A. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.  Hepatology. 1983;  3 656-662
• 7 Carman W F, Jacyna M R, Hadziyannis S et al.. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.  Lancet. 1989;  2 588-591
• 8 Brunetto M R, Stemler M, Bonino F et al.. A new hepatitis-B virus strain in patients with severe anti-Hbe positive chronic hepatitis-B.  J Hepatol. 1990;  10 258-261
• 9 Okamoto H, Yotsumoto S, Akahane Y et al.. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.  J Virol. 1990;  64 1298-1303
• 10 Tong S P, Li J S, Vitvitski L, Trepo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region.  Virology. 1990;  176 596-603
• 11 Fiordalisi G, Cariani E, Mantero G et al.. High genomic variability in the pre-C region of hepatitis B virus in anti-HBe, HBV DNA-positive chronic hepatitis.  J Med Virol. 1990;  31 297-300
• 12 Valliammai T, Thyagarajan S P, Zuckerman A J, Harrison T J. Precore and core mutations in HBV from individuals in India with chronic infection.  J Med Virol. 1995;  45 321-325
• 13 Li J S, Tong S P, Wen Y M, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe- minus mutant-possible contribution of a single nucleotide in the precore region.  J Virol. 1993;  67 5402-5410
• 14 Aikawa T, Kanai K, Kako M et al.. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild-type virus and precore mutant.  J Viral Hepat. 1995;  2 243-250
• 15 Lampertico P, Delninno E, Manzin A et al.. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.  Hepatology. 1997;  26 1621-1625
• 16 Okamoto H, Tsuda F, Akahane Y et al.. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen.  J Virol. 1994;  68 8102-8110
• 17 Li J, Buckwold V E, Hon M W, Ou J H. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation.  J Virol. 1999;  73 1239-1244
• 18 Takahashi K, Aoyama K, Ohno N et al.. The precore core promoter mutant (T(1762)A(1764)) of hepatitis B virus: clinical significance and an easy method for detection.  J Gen Virol. 1995;  76 3159-3164
• 19 Hsia C C, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma.  Lancet. 1996;  348 625-626
• 20 Fang Z L, Ling R, Wang S S, Nong J, Huang C S, Harrison T J. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China.  J Med Virol. 1998;  56 18-24
• 21 Fang Z L, Yang J Y, Ge X M et al.. Core promoter mutations (A(1762)T and G(1764)A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China.  J Med Virol. 2002;  68 33-40
• 22 Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.  Gastroenterology. 2003;  124 327-334
• 23 Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease.  J Virol. 1996;  70 8318-8331
• 24 Sendi H, Mehrab-Mohseni M, Zali M R, Norder H, Magnius L O. T-1764 G(1766) core promoter double mutants are restricted to hepatitis B virus strains with an A(1757) and are common in genotype D.  J Gen Virol. 2005;  86 2451-2458
• 25 Beath S V, Boxall E H, Watson R M, Tarlow M J, Kelly D A. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers.  BMJ. 1992;  304 1169-1170
• 26 Fagan E A, Smith P M, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBe-positive males.  Lancet. 1986;  2 538-540
• 27 Oren I, Hershow R C, Ben Porath E et al.. A common-source outbreak of fulminant hepatitis B in a hospital.  Ann Intern Med. 1989;  110 691-698
• 28 Kojima M, Shimizu M, Tsuchimochi T et al.. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants.  Vox Sang. 1991;  60 34-39
• 29 Sato S, Suzuki K, Akahane Y et al.. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis.  Ann Intern Med. 1995;  122 241-248
• 30 Liang T J, Hasegawa K, Rimon N, Wands J R, Ben Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis.  N Engl J Med. 1991;  324 1705-1709
• 31 Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B.  Hepatology. 1999;  29 1252-1258
• 32 Sterneck M, Gunther S, Santantonio T et al.. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation.  Hepatology. 1996;  24 300-306
• 33 Friedt M, Gerner P, Wintermeyer P, Wirth S. Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B.  BMC Gastroenterol. 2004;  4 11
• 34 Takahashi K, Akahane Y, Gotanda T et al.. Demonstration of hepatitis B e antigen in the core of Dane particles.  J Immunol. 1979;  122 275-279
• 35 Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis-B virus infection.  J Clin Invest. 1992;  89 332-338
• 36 Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus.  Adv Virus Res. 1999;  52 25-137
• 37 Suk F M, Lin M H, Newman M et al.. Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (197L) in human hepatitis B virus.  J Virol. 2002;  76 12069-12077
• 38 Le Pogam S, Yuan T T, Sahu G K, Chatterjee S, Shih C. Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein.  J Virol. 2000;  74 9099-9105
• 39 Rossner M T. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator.  J Med Virol. 1992;  36 101-117
• 40 Bruss V, Lu X Y, Thomssen R, Gerlich W H. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein.  EMBO J. 1994;  13 2273-2279
• 41 Lambert C, Mann S, Prange R. Assessment of determinants affecting the dual topology of hepadnaviral large envelope proteins.  J Gen Virol. 2004;  85 1221-1225
• 42 Neurath A R, Kent S B, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus.  Cell. 1986;  46 429-436
• 43 Chen Y CJ, Delbrook K, Dealwis C, Mimms L, Mushahwar I K, Mandecki W. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.  Proc Natl Acad Sci U S A. 1996;  93 1997-2001
• 44 Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr.  J Virol. 1987;  61 3030-3034
• 45 Carman W F, Zanetti A R, Karayiannis P et al.. Vaccine-induced escape mutant of hepatitis B virus.  Lancet. 1990;  336 325-329
• 46 Oon C J, Lim G K, Ye Z et al.. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore.  Vaccine. 1995;  13 699-702
• 47 McMahon G, Ehrlich P H, Moustafa Z A et al.. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients.  Hepatology. 1992;  15 757-766
• 48 Ghany M G, Ayola B, Villamil F G et al.. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology. 1998;  27 213-222
• 49 Protzer-Knolle U, Naumann U, Bartenschlager R et al.. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.  Hepatology. 1998;  27 254-263
• 50 Fernholz D, Galle P R, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier.  Virology. 1993;  194 137-148
• 51 Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate.  Cell. 1982;  29 403-415
• 52 Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus.  Nature. 1983;  305 827-829
• 53 Stuyver L J, Locarnini S A, Lok A et al.. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.  Hepatology. 2001;  33 751-757
• 54 Lok A SF, Lai C L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722
• 55 Ling R, Mutimer D, Ahmed N et al.. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.  Hepatology. 1996;  24 711-713
• 56 Tipples G A, Ma M M, Fischer K P, Bain V G, Kneteman N M, Tyrrell D L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.  Hepatology. 1996;  24 714-717
• 57 Buti M, Jardi R, Cotrina M, Rodriguezfrias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.  J Hepatol. 1998;  28 510-513
• 58 Melegari M, Scaglioni P P, Wands J R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.  Hepatology. 1998;  27 628-633
• 59 Ling R, Harrison T J. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.  J Gen Virol. 1999;  80 601-606
• 60 Niesters H GM, Deman R A, Pas S D, Fries E, Osterhaus ADME. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.  J Med Microbiol. 2002;  51 695-699
• 61 Bozdayi A M, Uzunalimoglu O, Turkyilmaz A R et al.. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.  J Viral Hepat. 2003;  10 256-265
• 62 Perrillo R, Schiff E, Yoshida E et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology. 2000;  32 129-134
• 63 Fung S K, Chae H B, Fontana R J et al.. Virologic response and resistance to adefovir in patients with chronic hepatitis B.  J Hepatol. 2006;  44 283-290
• 64 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
• 65 Villeneuve J P, Durantel D, Durantel S et al.. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.  J Hepatol. 2003;  39 1085-1089
• 66 Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models.  J Antimicrob Chemother. 2005;  55 608-611
• 67 Seifer M, Hamatake R K, Colonno R J, Standring D N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.  Antimicrob Agents Chemother. 1998;  42 3200-3208
• 68 Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection.  Curr Med Res Opin. 2005;  21 1845-1856
• 69 Torresi J, Earnest-Silveira L, Deliyannis G et al.. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.  Virology. 2002;  293 305-313
• 70 Torresi J, Earnest-Silveira L, Civitico G et al.. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.  Virology. 2002;  299 88-99